Haleon plc

What does Haleon own?
Haleon owns a portfolio of approximately 24 global and regional consumer health brands across five categories: oral health, vitamins and supplements, pain relief, respiratory health, and digestive health. Key brands include Sensodyne (sensitivity toothpaste), Panadol (pain relief), Centrum (multivitamins), Advil (ibuprofen), Voltaren (topical pain relief), Otrivin (nasal decongestant), Parodontax (gum health), Polident and Poligrip (denture care), Aquafresh (oral care), and Emergen-C (vitamin C). Products are sold in more than 170 countries.

Is Haleon publicly traded?
Yes, Haleon plc is listed on the London Stock Exchange under ticker HLN, with American Depositary Shares also listed on the New York Stock Exchange under the same ticker. Haleon completed its listing on the London Stock Exchange on 18 July 2022, in what was the largest London Stock Exchange listing in over a decade. The company does not have a controlling shareholder, and its shares are held primarily by institutional investors.

Who founded Haleon?
Haleon was formed through the demerger of GSK's consumer healthcare division in July 2022 and does not have a traditional founder. The consumer healthcare business that became Haleon was assembled by GSK and Pfizer through decades of acquisitions. In 2019, GSK and Pfizer combined their consumer healthcare businesses into a joint venture, which was subsequently demerged as Haleon in 2022. Brian McNamara, who had led the GSK Consumer Healthcare joint venture, became CEO of Haleon at the time of the demerger.

Where is Haleon headquartered?
Haleon is headquartered in Weybridge, Surrey, United Kingdom. The company's registered office and principal executive offices are located in Weybridge. Haleon operates manufacturing facilities in the United Kingdom, the United States, India, Germany, Ireland, and China, among other locations. The company sells products in more than 170 countries through a global commercial organization.

How many brands does Haleon own?
Haleon owns approximately 24 global and regional consumer health brands. The company's portfolio is concentrated in five categories: oral health (Sensodyne, Parodontax, Polident, Poligrip, Aquafresh), vitamins and supplements (Centrum, Caltrate, Emergen-C), pain relief (Advil, Panadol, Voltaren), respiratory health (Otrivin, Theraflu, Robitussin), and digestive health (Nexium Control, Tums). The company's strategy is to build global scale in a small number of category-leading brands rather than operate a large number of smaller brands.

Who owns Haleon?
Haleon plc is a publicly traded company with no controlling shareholder. At the time of the July 2022 demerger, GSK plc and Pfizer Inc. each retained significant stakes in Haleon, but both companies have been reducing their positions over time. As of early 2026, both GSK and Pfizer have substantially reduced their stakes. The remaining shares are held by institutional investors and public shareholders. The company's board includes a majority of independent non-executive directors.

Haleon's history as an independent company is brief, having been formed in July 2022, but its constituent brands have histories spanning decades and in some cases over a century.

The consumer healthcare division that became Haleon was assembled primarily through two major transactions. GSK (formerly GlaxoSmithKline) had built a consumer healthcare portfolio through decades of acquisitions, including the purchase of Beecham Group in 1989, which brought brands including Panadol and Aquafresh. In 2019, GSK and Pfizer combined their consumer healthcare businesses into a joint venture, with GSK holding a 68% stake and Pfizer holding 32%. This joint venture brought Pfizer's consumer health brands, including Advil, Centrum, Caltrate, and Emergen-C, into the combined portfolio.

The joint venture was named GSK Consumer Healthcare and operated as a standalone business unit within GSK from 2019. In 2021, GSK announced plans to demerge the consumer healthcare business as an independent publicly listed company, separating it from GSK's pharmaceutical and vaccines businesses. The rationale was that the consumer health business had different growth characteristics, capital requirements, and investor profiles from the prescription pharmaceutical business.

Haleon plc was incorporated and listed on the London Stock Exchange on 18 July 2022, in what was the largest London Stock Exchange listing in over a decade. GSK distributed shares in Haleon to its own shareholders, and Pfizer retained a stake in the newly independent company. Brian McNamara was appointed as CEO of Haleon at the time of the demerger, having previously served as CEO of GSK Consumer Healthcare.

Following the demerger, Haleon focused on establishing itself as an independent company with its own management team, governance structure, and strategic priorities. The company's initial strategic framework focused on organic revenue growth through innovation, geographic expansion, and increased investment in its leading brands.

In 2023 and 2024, Haleon continued to deliver organic revenue growth above its medium-term guidance range of 4% to 6%, driven by strong performances from Sensodyne, Centrum, and Voltaren. The company also began returning capital to shareholders through share buyback programs.

For the full year 2025, Haleon reported organic revenue growth of approximately 4%, with particularly strong performances from Sensodyne in India and China, Centrum Daily Kits in China, and Voltaren globally. The company's oral health segment delivered double-digit growth, driven by the continued rollout of Sensodyne's Clinical Platform innovation.

Haleon inherited certain legal liabilities from its predecessor companies at the time of the demerger from GSK. The most significant of these relates to Zantac (ranitidine), a heartburn medication that was sold under various brands including Zantac by GSK's consumer healthcare division before being withdrawn from the market in 2020 following concerns about the presence of a potential carcinogen. Haleon has faced litigation related to Zantac claims, and the company has set aside provisions to address these liabilities. GSK and Pfizer have indemnified Haleon for a portion of these liabilities under the terms of the demerger agreement.

Haleon's products are subject to regulatory oversight by health authorities in each market where they are sold, including the US Food and Drug Administration, the European Medicines Agency, and equivalent bodies in other countries. The company's consumer health products must comply with labeling, safety, and efficacy requirements in each jurisdiction.